1978 1980 1981 1982 1983 1984

1985 1986 1987 1988 1989 1990

1992 1993 1994 1995 1996 1997

1998 1999 2000 2001 2002 2003

2004 2005 2006 2007 2008

Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies.
Leibovich BC, Blute ML, Bostwick DG, Wilson TM, Pisansky TM, Davis BJ, Ramnani DM, Cheng L, Sebo TJ, Zincke H.

Human acid ceramidase is overexpressed but not mutated in prostate cancer.
Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W.

Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
Bostwick DG.

Clinical and pathologic aspects of spontaneous canine prostate carcinoma: a retrospective analysis of 76 cases.
Cornell KK, Bostwick DG, Cooley DM, Hall G, Harvey HJ, Hendrick MJ, Pauli BU, Render JA, Stoica G, Sweet DC, Waters DJ.

Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy.
Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG.

Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee.
Srigley JR, Amin MB, Bostwick DG, Grignon DJ, Hammond ME.

Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999.
Bostwick DG, Grignon DJ, Hammond ME, Amin MB, Cohen M, Crawford D, Gospadarowicz M, Kaplan RS, Miller DS, Montironi R, Pajak TF, Pollack A, Srigley JR, Yarbro JW.

Antioxidant enzyme expression and reactive oxygen species damage in prostatic intraepithelial neoplasia and cancer.
Bostwick DG, Alexander EE, Singh R, Shan A, Qian J, Santella RM, Oberley LW, Yan T, Zhong W, Jiang X, Oberley TD.

High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers.
Halmos G, Schally AV, Sun B, Davis R, Bostwick DG, Plonowski A.

Transurethral hot-water balloon thermoablation for benign prostatic hyperplasia: patient tolerance and pathologic findings.
Corica FA, Cheng L, Ramnani D, Pacelli A, Weaver A, Corica AP, Corica AG, Larson TR, O'Toole K, Bostwick DG.

Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines.
Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF 3rd, Emmert-Buck MR.

Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer.
Leibovich BC, Cheng L, Weaver AL, Myers RP, Bostwick DG.

Prostatic intraepithelial neoplasia: animal models 2000.
Bostwick DG, Ramnani D, Qian J.

Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary?
Davis BJ, Haddock MG, Wilson TM, Rothenberg HJ, Bostwick DG, Herman MG, Pisansky TM.

Predicting the survival of bladder carcinoma patients treated with radical cystectomy.
Cheng L, Weaver AL, Leibovich BC, Ramnani DM, Neumann RM, Scherer BG, Nehra A, Zincke H, Bostwick DG.

The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy.
Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG.

Prostatic intraepithelial neoplasia.
Bostwick DG.

Molecular profiling of clinical tissues specimens: feasibility and applications.
Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, Bostwick DG, Brown MR, Buetow KH, Chuaqui RF, Cole KA, Duray PH, Englert CR, Gillespie JW, Greenhut S, Grouse L, Hillier LW, Katz KS, Klausner RD, Kuznetzov V, Lash AE, Lennon G, Linehan WM, Liotta LA, Marra MA, Munson PJ, Ornstein DK, Prabhu VV, Prang C, Schuler GD, Soares MB, Tolstoshev CM, Vocke CD, Waterston RH.

Positive and negative biopsies in the pre-prostate specific antigen and prostate specific antigen eras, 1980 to 1997.
Roberts RO, Bergstralh EJ, Peterson NR, Bostwick DG, Lieber MM, Jacobsen SJ.

Predicting extravesical extension of bladder carcinoma: a novel method based on micrometer measurement of the depth of invasion in transurethral resection specimens.
Cheng L, Weaver AL, Bostwick DG.

Molecular profiling of clinical tissue specimens: feasibility and applications.
Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, Bostwick DG, Brown MR, Buetow KH, Chuaqui RF, Cole KA, Duray PH, Englert CR, Gillespie JW, Greenhut S, Grouse L, Hillier LW, Katz KS, Klausner RD, Kuznetzov V, Lash AE, Lennon G, Linehan WM, Liotta LA, Marra MA, Munson PJ, Ornstein DK, Prabhu VV, Prange C, Schuler GD, Soares MB, Tolstoshev CM, Vocke CD, Waterston RH.

Squamous papilloma of the urinary tract is unrelated to condyloma acuminata.
Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Nehra A, Malek RS, Zincke H, Bostwick DG.

Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma.
Cheng L, Neumann RM, Nehra A, Spotts BE, Weaver AL, Bostwick DG.

World Health Organization and International Society of Urological Pathology classification and two-number grading system of bladder tumors: reply.
Cheng L, Bostwick DG.

10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer.
Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N.

Sampling, submission, and report format for multiple prostate biopsies: a 1999 survey.
Iczkowski KA, Bostwick DG.

In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes.
Larson TR, Rrobertson DW, Corica A, Bostwick DG.

Prostate-specific antigen as a marker of prostate disease.
Montironi R, Mazzucchelli R, Algaba F, Bostwick DG, Krongrad A.

Atypical nephrogenic metaplasia of the urinary tract: a precursor lesion?
Cheng L, Cheville JC, Sebo TJ, Eble JN, Bostwick DG.

Paraganglioma of the urinary bladder: can biologic potential be predicted?
Cheng L, Leibovich BC, Cheville JC, Ramnani DM, Sebo TJ, Neumann RM, Nascimento AG, Zincke H, Bostwick DG.

Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens.
Cheng L, Neumann RM, Weaver AL, Cheville JC, Leibovich BC, Ramnani DM, Scherer BG, Nehra A, Zincke H, Bostwick DG.

Flat intraepithelial lesions of the urinary bladder.
Cheng L, Cheville JC, Neumann RM, Bostwick DG.

High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers.
Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG.

Extranodal extension in lymph node-positive prostate cancer.
Cheng L, Pisansky TM, Ramnani DM, Leibovich BC, Cheville JC, Slezak J, Bergstralh EJ, Zincke H, Bostwick DG.

Criteria for biopsy diagnosis of minimal volume prostatic adenocarcinoma: analytic comparison with nondiagnostic but suspicious atypical small acinar proliferation.
Iczkowski KA, Bostwick DG.

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma.
Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H.

Diagnosis of prostatic intraepithelial neoplasia: Prostate Working Group/consensus report.
Bostwick DG, Montironi R, Sesterhenn IA.

Cellular and molecular pathology of prostate cancer precursors.
Foster CS, Bostwick DG, Bonkhoff H, Damber JE, van der Kwast T, Montironi R, Sakr WA.

Epidemiology of high-grade prostatic intraepithelial neoplasia.
Sakr WA, Billis A, Ekman P, Wilt T, Bostwick DG.

Prostatic intraepithelial neoplasia: the preinvasive stage of prostate cancer. Overview of the prostate committee report.
Bostwick DG, Norlen BJ, Denis L.